ResearchMoz added Latest Research Report titled ” Prostate Cancer Market to 2021 – Increasing Disease Prevalence to be a Key Driver of Market Growth ” to it’s Large Report database.
Prostate Cancer (PC) is a disease predominately of the elderly with 60% of cases diagnosed in men aged 65 or over. Prostate cancer is slow growing, and asymptomatic at its earliest stages. However, with the use of digital rectal examination, the PSA test, and the incidental discovery of tumors following resection of the prostate, the majority of PC cases are diagnosed at an early stage (60%). As PC is slow growing, many patients can leave their disease untreated for extended periods of time with frequent monitoring (watchful waiting or active surveillance), with many patients dying from other causes before treatment is indicated. Surgery and/or radiotherapy is often curative when treatment is indicated for localized disease, with androgen deprivation being the standard of first-line care. However, most patients ultimately develop resistant disease, for whom treatment options have historically been limited, with treatment with docetaxel being standard. The recent approval of Zytiga and Xtandi for docetaxel refractory disease in 2011 and 2012 have improved survival of resistant patients, but there is a clear clinical need to diversify the treatment options for this patient cohort.
Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=494550
The current late-stage drugs in development for PC address this clinical need, however, results so far have been mixed, with none demonstrating clinically transformative efficacy of safety. As a result, the growth in PC prevalence as a result of a global aging population is expected to be the key driver of this market throughout the forecast period.
- Global revenues for the PC market are forecast to rise at a moderate CAGR of 9.5% from $7.6bn in 2014 to $13.6bn in 2021.
- What factors are driving the market growth?
- How can the factors limiting growth be overcome in the future?
- The pipeline addresses clinical need in the market; seven of the nine late-stage pipeline products are being developed as therapies for metastatic castration resistant disease.
- What other gaps in the market are being addressed by the current pipeline dynamics?
- The variation in molecule type has shifted away from small molecules (predominately hormonal therapies), the dominance of which has decreased from 91% across marketed products to 50% across the pipeline.
Read All Cancer Market Research Reports @ http://www.researchmoz.us/cancer-market-reports.html
Table of Contents
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 10
2.1 Disease Introduction 10
2.2 Symptoms and Risk Factors 10
2.3 Etiology and Pathophysiology 11
2.4 Diagnosis 13
2.4.1 Digital Rectal Examination 13
2.4.2 Imaging 13
2.4.3 Biopsy 13
2.4.4 Tumor Markers 14
2.5 Disease Staging and Risk Assessment 15
2.6 Treatment Algorithm 17
2.6.1 Localized or Locally Advanced Prostate Cancer 17
2.6.2 Hormone Sensitive Metastatic Prostate Cancer 19
2.6.3 Metastatic Castration Resistant Prostate Cancer 23
2.6.4 Heat Map – Marketed Products Overview 27
ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Mr. Nachiket Ghumare
90 State Street, Albany NY, United States – 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/